ArticleThe Journal of infectious diseases2010
Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni.
Article in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Host determinants of reinfection with schistosomes in humans: a systematic review and meta-analysis.PLoS neglected tropical diseases · 2014Pooled it
- Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions.The American journal of tropical medicine and hygiene · 2015Trial
- Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel.PLoS neglected tropical diseases · 2011Trial
- FcεRII (CD23) in dermatological disorders: structure, function, and clinical implications.Frontiers in allergy · 2026Review
- Mass drug administration of praziquantel lowers the susceptibility of school-aged children toFrontiers in immunology · 2026Article
- Can antibody conjugated nanomicelles alter the prospect of antibody targeted therapy against schistosomiasis mansoni?PLoS neglected tropical diseases · 2023Article
- Variants of IL6, IL10, FCN2, RNASE3, IL12B and IL17B loci are associated with Schistosoma mansoni worm burden in the Albert Nile region of Uganda.PLoS neglected tropical diseases · 2023Article
- Expression of CD117 (c-Kit) on Circulating B Cells in Pediatric Schistosomiasis.Infection and immunity · 2022Article
- Praziquantel Treatment ofFrontiers in immunology · 2021Article
- Schistosomiasis Control: Leave No Age Group Behind.Trends in parasitology · 2020Review
- Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development.Research and reports in tropical medicine · 2020Review
- Effect of four rounds of annual school-wide mass praziquantel treatment for schistosoma mansoni control on schistosome-specific immune responses.Parasite immunology · 2018Article
- Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study.The American journal of tropical medicine and hygiene · 2018Article
- Paediatric schistosomiasis: What we know and what we need to know.PLoS neglected tropical diseases · 2018Review
- Host immunity, nutrition and coinfection alter longitudinal infection patterns of schistosomes in a free ranging African buffalo population.PLoS neglected tropical diseases · 2017Article
- The Interdependence between Schistosome Transmission and Protective Immunity.Tropical medicine and infectious disease · 2017Review
- Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens.PLoS neglected tropical diseases · 2017Article
- Immuno-evasive tactics by schistosomes identify an effective allergy preventative.Experimental parasitology · 2015Article
- No apparent reduction in schistosome burden or genetic diversity following four years of school-based mass drug administration in mwea, central kenya, a heavy transmission area.PLoS neglected tropical diseases · 2014Article
- Immunology of human schistosomiasis.Parasite immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundAge prevalence curves for areas in which schistosomiasis is endemic suggest that humans develop partial immunity to reinfection beginning in early adolescence. We conducted a 2-year longitudinal study to determine whether children infected with Schistosoma mansoni develop protection-related immune responses after treatment with praziquantel and whether the development of these immune responses is accelerated by frequent treatment after reinfection.
methodsChildren (8-10 years old) were tested for S. mansoni every 4 months and treated with praziquantel when positive (arm A; n=68) or were tested and treated at the end of the 2-year follow-up period (arm B; n=49).
resultsChildren in arm A who remained free of infection during follow-up had significantly higher baseline levels of schistosome-specific immunoglobulin E (IgE) than did children with > or =2 repeat diagnoses of S. mansoni infection. Children with > or =2 repeat diagnoses of S. mansoni infection had significantly increased levels of anti-schistosome IgE and CD23(+) B cells after receiving > or =3 praziquantel treatments over the course of follow-up. No increase in either parameter was seen in children who received only the baseline praziquantel treatment.
conclusionsB cell activation and anti-schistosome IgE are associated with resistance to S. mansoni in children, and these immunological parameters can be increased by multiple rounds of infections and praziquantel-induced cures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.